**Table S2. Distribution of Patient Global Impression of Change scores at the end of the double-blind efficacy phase (Last observation carried forward), Intent-to-treat analysis set**

|  | **PHN** | | | | **PTN** | |
| --- | --- | --- | --- | --- | --- | --- |
| **Placebo**  **N=20**  **n (%)** | **Fulranumab**  **1mgQ4wk**  **N=12**  **n (%)** | **Fulranumab**  **3mgQ4wk**  **N=13**  **n (%)** | **Fulranumab**  **10mgQ4wk**  **N=19**  **n (%)** | **Placebo**  **N=21**  **n (%)** | **Fulranumab**  **10mgQ4wk**  **N=23**  **n (%)** |
| 1 – very much improved | 1 (5) | 0 | 1 (8) | 0 | 3 (14) | 1 (4) |
| 2 – much improved | 4 (20) | 3 (25) | 1 (8) | 5 (26) | 4 (19) | 2 (9) |
| 3 – minimally improved | 4 (20) | 3 (25) | 1 (8) | 3 (16) | 5 (24) | 7 (30) |
| 4 – not changed | 11 (55) | 5 (42) | 9 (69) | 10 (53) | 9 (43) | 11 (48) |
| 5 – minimally worse | 0 | 0 | 0 | 1 (5) | - |  |
| 6 – much worse | 0 | 1 (8) | 1 (8) | 0 | 0 | 2 (9) |

Percentages calculated with the number of patient per time interval as denominator; N, number of patients; n, number of patients in each group; PHN, postherpetic neuralgia; PTN, posttraumatic neuralgia